01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech companies...
22:04 , Oct 4, 2018 |  BC Extra  |  Company News

Management tracks: Grail, Nimbus

Cancer detection company Grail Inc. (Menlo Park, Calif.) hired Renée Galá as its first CFO, effective Jan. 3. Gala is SVP and CFO at Theravance Biopharma Inc. (NASDAQ:TBPH). Grail launched in 2016 and has raised...
23:05 , Aug 1, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: July 2018

New Therapeutic Targets and Biomarkers: July 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2018. Therapeutic targets are defined as any protein, gene or other...
22:52 , Jul 20, 2018 |  BioCentury  |  Finance

JOBS Jolt 3.0?

The latest iteration of the JOBS Act could make it easier for biotechs to go public -- and raise more money more quickly -- but that doesn’t necessarily mean the quality of the IPO queue...
17:12 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Allakos spikes after pricing upsized IPO above range

Allakos Inc. (NASDAQ:ALLK) gained $13.25 (74%) to $31.25 July 19 after it raised $128.4 million through the sale of 7.1 million shares at $18 in an upsized IPO. Goldman Sachs, Jefferies and William Blair are...
14:27 , Jul 19, 2018 |  BC Extra  |  Financial News

Allakos spikes after pricing upsized IPO above range

Allakos Inc. (NASDAQ:ALLK) gained $13.25 (74%) to $31.25 Thursday after it raised $128.4 million through the sale of 7.1 million shares at $18 in an upsized IPO. Goldman Sachs, Jefferies and William Blair are underwriters....
21:39 , Jun 23, 2018 |  BC Extra  |  Financial News

Latest batch of IPO filings: Rubius, Constellation, Replimune, Allakos

As a busy week for IPO pricings came to a close, several more companies filed for NASDAQ listings late Friday, further stocking an IPO pipeline of companies likely to seek liquidity during a tight calendar...
19:31 , Jun 15, 2018 |  BC Week In Review  |  Financial News

Alta closes $130M fund for biotechs, tech-based healthcare services

Alta Partners (San Francisco, Calif.) closed its Alta Partners NextGen Fund I at $130 million to invest in biotech and healthcare delivery companies. Alta told BioCentury the fund will invest in about six to eight...
21:13 , Jun 12, 2018 |  BC Extra  |  Financial News

Alta closes $130M fund for biotechs, tech-based healthcare services

Alta Partners closed its Alta Partners NextGen Fund I at $130 million to invest in biotech and healthcare delivery companies. Alta told BioCentury the fund will invest in about six to eight companies. Alta has...
14:48 , Apr 6, 2018 |  BC Week In Review  |  Clinical News

Allakos reports Phase I data for AK002 in healthy volunteers

Allakos Inc. (San Carlos, Calif.) reported data from a Phase I trial in healthy volunteers showing that single doses of 0.001-1 mg/kg IV AK002 were generally well tolerated. The company is developing the non-fucosylated IgG1...